Immatics N.V.
IMTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.3B
$9.56
▲ +1.06%
P/E
-4.95
Mkt Cap
$1.3B
52-Wk Range
$5.67–$12.41
52-Week Range
$5.67 - $12.41
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 64.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary TCR discovery and engineering platform with deep immunology expertise
- Strategic collaborations with pharmaceutical giants (GSK, Celgene, Genmab) providing validation and resources
- Differentiated approach targeting multiple solid tumor indications with multiple product candidates
- Clinical-stage pipeline with multiple candidates in active development reducing single-asset risk
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Clinical trial advancement and regulatory approval of ACTengine candidates (IMA201, IMA202, IMA203)
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+3.7% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IMTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 17, 2026
AUG 18, 2026
Reported EPS of -$0.53 vs -$0.47 consensus (-11.6% surprise). Revenue of $11.9M vs $12.4M expected (-4.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-11.6%
Revenue trend · last 8Q
—
—
—
-39%
-75%
-90%
-65%
-64%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$22.0M
$59.3M
$65.9M
$21.8M
$5.6M
$6.1M
$23.2M
$7.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
-759.5%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Chardan Capital · May 19, 2026
vs Industry
How IMTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related